Emerging Therapies eBook
Read the article: Navigating the Intricacies of Lentiviral CGTs
Read the eBook: BioPharm International’s September 2023 Emerging Therapies eBook
CONTINUE TO SITE
OR WAIT null SECS
Advertisement
- About Us
- Advertise
- Editorial Information
- Contact Us
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2024 MJH Life Sciences™ and BioPharm International. All rights reserved.
Navigating the Intricacies of Lentiviral CGTs
Published on:
Marwan Alsarraj
BioPharm International, Emerging Therapies, September 2023 eBook, Volume 2023 eBook, Issue 3
Pages: 14–17
Scientists are leveraging ddPCR technology to get an accurate read on viral titer and vector copy number.
Cell and gene therapies (CGTs) can potentially treat, and sometimes even cure, a wide range of genetic and acquired diseases ranging from immunodeficiencies to cancer. For this reason, the field has been growing at an astronomical rate. Having impeccable data about the makeup of a new therapeutic is vital to successful clinical trials that take a new drug candidate one step closer to FDA approval. But the myriad designs of CGTs in development today make that uniquely challenging. In this article, the author will explore some of the specific hurdles associated with lentiviral CGTs.
Read this article in BioPharm International®’s September 2023 Emerging Therapies eBook.
Advertisement
About the author
Marwan Alsarraj is biopharma segment manager, Digital Biology Group, Bio-Rad.
Article details
BioPharm International
eBook: Emerging Therapies
September 2023
Pages: 14–17
Citation
When referring to this article, please cite it as Alsarraj, M. Navigating the Intricacies of Lentiviral CGTs. BioPharm International’s Emerging Therapies eBook. September 2023.
